Zobrazeno 1 - 6
of 6
pro vyhledávání: '"You-Tien Tsai"'
Publikováno v:
Aging. 15:830-845
Publikováno v:
Oxidative Medicine and Cellular Longevity, Vol 2022 (2022)
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity
Background. Vascular calcification (VC) constitutes subclinical vascular burden and increases cardiovascular mortality. Effective therapeutics for VC remains to be procured. We aimed to use a deep learning-based strategy to screen and uncover plant c
Autor:
Tzu-Hang Yuan, Hsiang-Yuan Yeh, Pei-Huan Chuang, Huei-Wen Chen, You-Tien Tsai, Chia-Ter Chao, Jenq-Wen Huang
Publikováno v:
Cell Death Discovery, Vol 5, Iss 1, Pp 1-11 (2019)
Cell Death Discovery
Cell Death Discovery
Vascular calcification (VC) is highly prevalent in patients with advanced age, or those with chronic kidney disease and diabetes, accounting for substantial global cardiovascular burden. The pathophysiology of VC involves active mineral deposition by
Publikováno v:
Oxidative Medicine and Cellular Longevity, Vol 2021 (2021)
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity
Vascular calcification (VC) describes the pathophysiological phenotype of calcium apatite deposition within the vascular wall, leading to vascular stiffening and the loss of compliance. VC is never benign; the presence and severity of VC correlate cl
Autor:
You-Tien Tsai, Huei-Wen Chen, Jenq-Wen Huang, Hsiang-Yuan Yeh, Min-Tser Liao, Tzu-Hang Yuan, Chia-Ter Chao
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 8530, p 8530 (2020)
Volume 21
Issue 22
International Journal of Molecular Sciences, Vol 21, Iss 8530, p 8530 (2020)
Volume 21
Issue 22
Vascular calcification (VC) is a critical contributor to the rising cardiovascular risk among at-risk populations such as those with diabetes or renal failure. The pathogenesis of VC involves an uprising of oxidative stress, for which antioxidants ca
Publikováno v:
Cardiovasc Res
Aims Vascular calcification (VC) increases the future risk of cardiovascular events in uraemic patients, but effective therapies are still unavailable. Accurate identification of those at risk of developing VC using pathogenesis-based biomarkers is o